Medscape1d
Tocilizumab: The First Interleukin-6-Receptor Inhibitor
Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...
clinicaladvisor.com8d
FDA Approves Tocilizumab Biosimilar Avtozma
The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.
Hosted on MSN15d
Celltrion’s Avtozma receives FDA approval for multiple conditions
The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.
pharmaphorum2d
EU has its first RoActemra biosimilar, from Fresenius Kabi
The biosimilar of IL-6 inhibitor tocilizumab, called Tyenne (formerly MSB11456), has been approved for the same indications as Roche’s brand, including rheumatoid arthritis, systemic juvenile ...
National Institute for Health and Care Excellence1y
Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]
Reason for decision Not eligible for Health Technology Evaluation guidance Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal ...
PipelineReview.com7d
U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...